Cardiol Therapeutics Inc. income statement

In fiscal 2021, Cardiol Therapeutics Inc. reported revenue of $62,858, operating income of −$30.9m (a -49091.9% margin) and net income of −$25.3m, or −$0.58 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cardiol Therapeutics Inc.: income statement, annual
Fiscal year	2021Dec 2021
Revenue	0
Research and development	9
Operating income	−31
Income tax	0
Net income	−25
Diluted EPS	−$0.58
Diluted shares (average)	43m
EBITDA	−31

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Cardiol Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cardiol Therapeutics Inc.